FCG Investment Co Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

FCG Investment Co boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 11,240 shares of the biopharmaceutical company’s stock after buying an additional 1,003 shares during the period. FCG Investment Co’s holdings in Gilead Sciences were worth $1,038,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Lifestyle Asset Management Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $228,000. Veracity Capital LLC raised its stake in shares of Gilead Sciences by 58.2% during the fourth quarter. Veracity Capital LLC now owns 8,733 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 3,213 shares during the last quarter. Donoghue Forlines LLC boosted its holdings in shares of Gilead Sciences by 51.2% during the fourth quarter. Donoghue Forlines LLC now owns 39,954 shares of the biopharmaceutical company’s stock worth $3,691,000 after purchasing an additional 13,524 shares during the period. Goldstein Advisors LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter worth about $218,000. Finally, Avior Wealth Management LLC grew its stake in shares of Gilead Sciences by 33.2% in the fourth quarter. Avior Wealth Management LLC now owns 12,551 shares of the biopharmaceutical company’s stock worth $1,140,000 after purchasing an additional 3,129 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 over the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $92.92 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The firm’s 50-day moving average is $91.63 and its 200 day moving average is $84.63. The stock has a market cap of $115.80 billion, a price-to-earnings ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analysts Set New Price Targets

Several research firms have weighed in on GILD. UBS Group increased their price objective on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. The Goldman Sachs Group upped their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Wolfe Research began coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Finally, Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.